ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptive Biotechnologies Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)
Close on Oct 19, 2026
- Market cap
- $3.83B
- P/E (TTM)
- –
- Dividend yield
- –
Adaptive Biotechnologies Corp cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 75.6%
- Operating margin
- -12.2%
- Net margin
- -20.7%
- Return on equity, FY2025
- -28.2%
Financial strength
- Current ratio
- 4.79
- Debt to equity
- 0.00
- Debt to assets
- 0.0%
- Cash to current liabilities
- 193.7%
Valuation
- P/E ratio
- –
- Price to sales
- 12.43
- Price to book
- 26.79
- Dividend yield
- –